1+ min ago   (81+ words) Bladder cancer remains one of the most challenging malignancies in modern urology, and a newly published comprehensive review in the Journal of Translational Medicine argues that the field is standing at the threshold of a diagnostic revolution. The review, led…...

1+ hour, 29+ min ago   (55+ words) Hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the world’s most lethal malignancies, and its treatment options have changed surprisingly little over the past two decades. Now, a review published in Medical Oncology argues that…...

1+ hour, 33+ min ago   (650+ words) A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine....

1+ hour, 45+ min ago   (69+ words) Small-cell lung cancer has long been one of oncology’s most punishing adversaries. It grows with astonishing speed, spreads early, and presents a treatment paradox that has frustrated clinicians for decades: at diagnosis, tumors melt away under platinum-based chemotherapy, yet relapse…...

1+ hour, 48+ min ago   (672+ words) For decades, surgeons have operated on the assumption that when it comes to removing lymph nodes in cancer surgery, more is better. A thorough lymph node dissection has long been considered the gold standard, ensuring accurate staging and reducing the…...

1+ hour, 56+ min ago   (55+ words) Pembrolizumab, one of the most widely prescribed cancer immunotherapies in the world, has long been dosed on the assumption that saturating the PD-1 receptor on T cells is the key to unlocking the immune system against tumours. A new translational…...

2+ hour, 36+ min ago   (101+ words) Higher income has long been treated as a reliable shield against chronic disease, but a sweeping new analysis of female breast cancer survivors in the United States suggests that this protection is anything but uniform. Drawing on four years of…...

2+ hour, 54+ min ago   (55+ words) Immunotherapy has transformed the outlook for people with advanced bladder and kidney cancer. Drugs known as immune checkpoint inhibitors, which block molecular brakes such as CTLA-4, PD-1 and PD-L1 to unleash the immune system against tumours, have dramatically improved long-term…...

3+ hour, 15+ min ago   (53+ words) Triple-negative breast cancer is the form of the disease that clinicians fear most. Lacking the three molecular targets — the estrogen receptor, the progesterone receptor and the HER2 protein — that anchor modern targeted therapies, it leaves patients with fewer options and a…...

3+ hour, 32+ min ago   (55+ words) Immune checkpoint inhibitors have rewritten the outlook for some patients with gastrointestinal cancers, turning once uniformly fatal diagnoses into manageable chronic conditions for a fortunate minority. Yet for every dramatic response there are many more patients whose tumours barely flinch,…...